Drug Information

Drug General Information
Drug ID
D05GBV
Former ID
DIB011403
Drug Name
RDX-5791
Indication Constipation [ICD9: 564; ICD10:K59.0] Phase 2 [523444]
Company
Ardelyx; astrazeneca
Structure
Download
2D MOL

3D MOL
Canonical SMILES
CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O<br />)NCCOCCOCCNS(=O)(=O)c3cccc(c3)[C@@H]4CN(C)Cc5c(Cl)cc(Cl<br />)cc45)c6cc(Cl)cc(Cl)c6C1
InChI
1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
InChIKey
DNHPDWGIXIMXSA-CXNSMIOJSA-N
Target and Pathway
Target(s) Sodium/hydrogen exchanger 3 Target Info Modulator [550792]
KEGG Pathway Proximal tubule bicarbonate reclamation
Protein digestion and absorption
Bile secretion
Mineral absorption
Pathway Interaction Database Endothelins
RhoA signaling pathway
WikiPathways SIDS Susceptibility Pathways
References
Ref 523444ClinicalTrials.gov (NCT01340053) A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). U.S. National Institutes of Health.
Ref 550792RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.